NDLI: Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Eriksson, Sophie E. Ohlsson, Tomas Nilsson, Rune Tennvall, Jan
Description	Country affiliation: Sweden Author Affiliation: Eriksson SE ( Department of Oncology, Lund University, Sweden. sophie.eriksson@med.lu.se)
Abstract	AIM: Fractionation is generally used as a mean to improve radioimmunotherapy (RIT). Since RIT is considered suitable for small-volume disease, the aim of the current study was to investigate whether repeated administration of (177)Lu-labeled mAb BR96 was tolerated and could delay or prevent metastatic disease after complete remission of the tumor obtained by the first administration. METHODS: Immunocompetent rats bearing a syngeneic colon carcinoma were first treated with 400 MBq/kg (177)Lu-DOTA-BR96, an activity resulting in complete response in 29 of 30 animals. On day 21, two groups of rats were given an additional activity of 150 or 350 MBq/kg resulting in total administered activities corresponding to 0.9 and 1.3 times the maximal tolerated dose. RESULTS: The additional treatment resulted in tolerable myelotoxicity; however, the frequency of metastatic disease and survival were not affected. Immunohistochemistry demonstrated binding of the BR96 antibody to tissue sections of analyzed metastases. CONCLUSIONS: In our model, development of metastatic disease after treatment of the manifest tumor was not prevented by an additional treatment with the same radioimmunoconjugate. Therefore, the antibody should be labeled with a more suitable radionuclide for treatment of metastases. The repeated targeted therapy was well tolerated in aspects of myelotoxicity.
File Format	HTM / HTML
ISSN	10849785
Issue Number	2
Volume Number	27
e-ISSN	15578852
Journal	Cancer Biotherapy & Radiopharmaceuticals
Language	English
Publisher	Mary Ann Liebert, Inc.
Publisher Date	2012-03-01
Publisher Place	United States
Access Restriction	Subscribed
Subject Keyword	Discipline Pharmacology Discipline Oncology Antibodies, Monoclonal Administration & Dosage Carcinoma Radiotherapy Colonic Neoplasms Lutetium Radioimmunotherapy Methods Radioisotopes Animals Adverse Effects Blood Platelets Radiation Effects Body Weight Pathology Cell Line, Tumor Dose-response Relationship, Radiation Immunoconjugates Leukocytes Male Rats Rats, Inbred Bn Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging Cancer Research Pharmacology Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in